Thank you very much, Mr. Chair.
Where do we go from here? The PMPRB has been around for a while. We were talking about it on our first run-around. We've had some very good testimony here today—very emotional.
Ms. Little, thank you so much for your presentation on that as well.
It's hard to figure out where to start on this one. Maybe a quick question here is on how a lot of concepts are getting caught up in our discussion here. We've got expensive drugs, rare diseases and a rare disease strategy issue that we need to be talking about. I don't know if it belongs in here. It does, but it doesn't. We have the issue of pricing that belongs in here and it doesn't. We have the issue of this pharmacare that's been promised to Canadians on a number of different occasions. That's caught up in here. It's hard to figure out.
Maybe I'll go to IMC for a few minutes.
Where do you think things should go from here? If the government has already twice held back from expanding the regulations.... I have to figure out how to actually ask this question correctly. Do we hold them off again? I ask because I'm sure that holding them off twice now has created even more challenges within the system, because the system is probably very anxious on how pricing is going to happen, how the reviews are going to happen, how PMPRB is going to work. So is holding it off for another six months conducive to the companies? Maybe that's the first question for Pamela.